Fecal transplant for lymphoma patients getting CAR T therapy
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether giving a fecal transplant (a stool enema from a healthy donor) can improve the response to CAR T-cell therapy in people with B-cell lymphoma. It may help by restoring healthy gut bacteria that are often wiped out by strong antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and have B-cell lymphoma (a type of blood cancer).
- You are scheduled to receive a CAR T-cell therapy called axicabtagene ciloleucel (YesCAR T).
- You have received strong antibiotics for at least 2 days in the past 6 months (like meropenem, cefepime, or metronidazole).
- You are in fairly good health (able to care for yourself, up and about more than half the day).
- Your liver and kidneys are working well enough, and your blood counts are stable enough for a fecal enema.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new car t-cell treatment (axicabtagene ciloleucel) for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if this therapy can help control the lymphoma.
This study tests whether a fecal transplant (transferring healthy gut bacteria) can improve outcomes for people with certain lymphomas who have taken strong antibiotics and are about to get CAR T-cell therapy (Yescarta). The goal is to see if rebuilding gut bacteria helps the treatment work better.
This pilot study tests whether giving a fecal microbiota transplant before standard CAR-T therapy (for B-cell lymphoma) or reduced-intensity stem cell transplant (for AML or high-risk MDS) can improve treatment outcomes. It aims to see if restoring gut bacteria helps reduce complications.
This study tests whether giving a fecal microbiota transplant (a stool transplant from a healthy donor or someone who responded well to immunotherapy) together with the immunotherapy drug tislelizumab can help people with advanced or metastatic non-small cell lung cancer (NSCLC). It's for patients whose cancer grew after prior immunotherapy.
This trial tests whether a fecal microbiota transplant (FMT) can help overcome drug resistance in people with advanced liver cancer whose disease has worsened after a specific triple therapy (TACE, lenvatinib, and sintilimab). FMT involves transferring gut bacteria from a healthy donor to restore the balance of your gut microbiome, which may make your cancer more responsive to treatment again.
This trial tests whether combining fecal microbiota transplantation (FMT) with chemotherapy, radiotherapy, and immunotherapy before surgery can help shrink locally advanced rectal cancer that is MSS/pMMR. FMT involves transferring healthy donor stool to restore gut bacteria, which may boost treatment response.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.